Literature DB >> 8961914

Preliminary experience with low-dose methotrexate in fibroblastic rheumatism.

O Vittecoq1, O Mejjad, F da Silva, P Joly, E Thomine, P Lauret, J M Thomine, X le Loët.   

Abstract

Fibroblastic rheumatism (FR) is a rare disease characterized by joint manifestations without joint destruction, and associated with cutaneous nodules and sclerodactyly. The diagnosis is usually based on histologic examination of a skin nodule or synovium specimen. In the 11 previously reported cases, corticosteroid treatment, which has been widely used, was shown to have an unpredictable effect on the evolution of FR. We report a case of FR that was treated with methotrexate for 5 years, which led to complete recovery. This drug may be considered an effective treatment for FR. Further cases are needed to confirm this preliminary experience.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961914     DOI: 10.1002/art.1780391218

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  2 in total

1.  Good clinical response to methotrexate treatment in a patient with fibroblastic rheumatism.

Authors:  Juliane Aline Paupitz; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2010-03-26       Impact factor: 2.631

Review 2.  Fibroblastic rheumatism: an uncommon arthritis. A case-based review.

Authors:  A Pieta; A Zioga; A Skalkou; A I Venetsanopoulou; A A Drosos; P V Voulgari
Journal:  Rheumatol Int       Date:  2021-10-05       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.